UBS Group’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $96.2K | Sell |
|
|||||
|
2025
Q2 | $926K | Sell |
|
|||||
|
2025
Q1 | $475K | Buy |
|
|||||
|
2024
Q4 | $524K | Buy |
|
|||||
|
2024
Q3 | $81.6K | Sell |
|
|||||
|
2024
Q2 | $85.8K | Buy |
|
|||||
|
2024
Q1 | $44.7K | Buy |
|
|||||
|
2023
Q4 | $31.1K | Buy |
|
|||||
|
2023
Q3 | $24.1K | Sell |
|
|||||
|
2023
Q2 | $36.9K | Sell |
|
|||||
|
2023
Q1 | $40.5K | Sell |
|
|||||
|
2022
Q4 | $73.3K | Buy |
|
|||||
|
2022
Q3 | $26K | Buy |
|
|||||
|
2022
Q2 | $8K | Buy |
|
|||||
|
2022
Q1 | $5K | Sell |
|
|||||
|
2021
Q4 | $608K | Sell |
|
|||||
|
2021
Q3 | $800K | Buy |
|
|||||
|
2021
Q2 | $160K | Sell |
|
|||||
|
2021
Q1 | $630K | Buy |
|
|||||
|
2020
Q4 | $9K | Buy |
|
|||||
|
2020
Q3 | $8K | Hold |
|
|||||
|
2020
Q2 | $10K | Sell |
|
|||||
|
2020
Q1 | $174K | Sell |
|
|||||
|
2019
Q4 | $475K | Sell |
|
|||||
|
2019
Q3 | $658K | Buy |
|
|||||
|
2019
Q2 | $267K | Buy |
|
|||||
|
2019
Q1 | $130K | Sell |
|
|||||
|
2018
Q4 | $1.31M | Buy |
|
|||||
|
2018
Q3 | $219K | Buy |
|
|||||
|
2018
Q2 | $53K | Sell |
|
|||||
|
2018
Q1 | $1.31M | Buy |
|
|||||
|
2017
Q4 | $236K | Sell |
|
|||||
|
2017
Q3 | $278K | Buy |
|
|||||
|
2017
Q2 | $39K | Sell |
|
|||||
|
2017
Q1 | $53K | Sell |
|
|||||
|
2016
Q4 | $45K | Buy |
|
|||||
|
2016
Q3 | $14K | Buy |
|
|||||
|
2016
Q2 | – | Sell |
|
|||||
|
2016
Q1 | $5K | Sell |
|
|||||
|
2015
Q4 | $14K | Buy |
|